GeneDx Holdings Corp. (WGS) - Total Assets
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) holds total assets worth $481.49 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GeneDx Holdings Corp. - Total Assets Trend (2020–2025)
This chart illustrates how GeneDx Holdings Corp.'s total assets have evolved over time, based on quarterly financial data. Also see WGS stock market capitalisation for the company's overall valuation and market capitalisation.
GeneDx Holdings Corp. - Asset Composition Analysis
Current Asset Composition (December 2025)
GeneDx Holdings Corp.'s total assets of $481.49 Million consist of 47.1% current assets and 53.0% non-current assets. Review GeneDx Holdings Corp. total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.4% |
| Accounts Receivable | $74.37 Million | 13.0% |
| Inventory | $13.95 Million | 2.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $168.48 Million | 29.6% |
| Goodwill | $13.52 Million | 2.4% |
Asset Composition Trend (2020–2025)
This chart illustrates how GeneDx Holdings Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See WGS stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeneDx Holdings Corp.'s current assets represent 47.1% of total assets in 2025, a decrease from 69.2% in 2020.
- Cash Position: Cash and equivalents constituted 18.4% of total assets in 2025, down from 43.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 29.6% of total assets.
GeneDx Holdings Corp. Competitors by Total Assets
Key competitors of GeneDx Holdings Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468
|
China | CN¥1.76 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €439.78K |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
GeneDx Holdings Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.30 | 2.87 | 7.55 |
| Quick Ratio | 3.06 | 2.70 | 7.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $171.73 Million | $133.43 Million | $467.14 Million |
GeneDx Holdings Corp. - Advanced Valuation Insights
This section examines the relationship between GeneDx Holdings Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.26 |
| Latest Market Cap to Assets Ratio | 4.46 |
| Asset Growth Rate (YoY) | 36.0% |
| Total Assets | $570.19 Million |
| Market Capitalization | $2.54 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values GeneDx Holdings Corp.'s assets at a significant premium (4.46x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: GeneDx Holdings Corp.'s assets grew by 36.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GeneDx Holdings Corp. (2020–2025)
The table below shows the annual total assets of GeneDx Holdings Corp. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $570.19 Million | +35.96% |
| 2024-12-31 | $419.38 Million | +0.15% |
| 2023-12-31 | $418.76 Million | -23.20% |
| 2022-12-31 | $545.26 Million | -1.59% |
| 2021-12-31 | $554.09 Million | +120.19% |
| 2020-12-31 | $251.64 Million | -- |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and can… Read more